Ideaya Biosciences Inc (IDYA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.08B
Last updated: Nov 17, 2026 at 11:06 AM ET
Ideaya Biosciences Inc (IDYA) Financials: Revenue, Profit and Cash Flow
Ideaya Biosciences reported revenue of $218.71M for the fiscal year ended Dec 31, 2025, up 3024.4% from the year before. That year, net income was -$113.70M with a net margin of -52.0%, operating cash flow was -$71.10M and free cash flow was -$73.47M. The quarter ended Sep 30, 2026 had revenue of $10.24M and net income of -$125.75M.
Revenue and Margins
The operating margin was -72.8% in the fiscal year ended Dec 2025. Over the 5 years to Dec 2025, revenue grew from $19.54M, a compound annual rate of 62.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $218.71M | +3024.4% | 100.0% | -72.8% | -52.0% |
| Dec 2024 | $7.00M | -70.1% | 100.0% | -4671.1% | -3921.1% |
| Dec 2023 | $23.39M | -54.1% | 100.0% | -574.9% | -483.0% |
| Dec 2022 | $50.93M | +82.3% | 100.0% | -122.7% | -115.2% |
| Dec 2021 | $27.94M | +43.0% | 100.0% | -179.9% | -178.1% |
| Dec 2020 | $19.54M | N/A | 100.0% | -180.9% | -176.6% |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218.71M | $7.00M | $23.39M | $50.93M | $27.94M | $19.54M | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $391.00K |
| Gross profit | $218.71M | $7.00M | $23.39M | $50.93M | $27.94M | $19.54M | $0 | $0 | -$391.00K |
| Research and development | $314.70M | $294.67M | $129.51M | $89.54M | $58.16M | $39.70M | $34.32M | $31.75M | $12.38M |
| Operating income | -$159.31M | -$326.98M | -$134.43M | -$62.50M | -$50.27M | -$35.34M | -$44.27M | -$36.42M | -$14.44M |
| Net income | -$113.70M | -$274.48M | -$112.96M | -$58.66M | -$49.76M | -$34.49M | -$41.98M | -$34.35M | -$11.86M |
| EBITDA | -$119.08M | -$293.88M | -$120.51M | -$59.68M | -$44.90M | -$33.38M | -$43.50M | -$36.34M | -$11.47M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.24M | $8.86M | $6.56M | $10.88M | $207.83M | $0 | $0 | $7.00M | $0 | $0 | $0 | $3.92M |
| Gross profit | $10.24M | $8.86M | $6.56M | $10.88M | $207.83M | $0 | $0 | $7.00M | $0 | $0 | $0 | $3.92M |
| Operating income | -$137.63M | -$122.29M | -$108.54M | -$94.57M | $108.45M | -$88.81M | -$84.39M | -$144.14M | -$66.89M | -$64.93M | -$51.02M | -$41.91M |
| Net income | -$125.75M | -$112.45M | -$98.54M | -$83.27M | $119.24M | -$77.49M | -$72.18M | -$130.31M | -$51.82M | -$52.77M | -$39.57M | -$33.95M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $339.00K by $112.49M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.11B | $1.12B | $649.32M | $387.97M | $381.35M | $298.27M | $113.00M | $96.54M | $17.48M |
| Current assets | $666.73M | $689.71M | $532.63M | $370.45M | $251.00M | $288.61M | $101.65M | $90.67M | $13.58M |
| Cash and equivalents | $112.83M | $84.38M | $157.02M | $68.63M | $92.05M | $72.04M | $34.07M | $20.50M | $5.96M |
| Total liabilities | $86.39M | $64.94M | $28.23M | $38.51M | $79.83M | $100.00M | $12.60M | $7.10M | $33.22M |
| Short-term debt | $339.00K | $298.00K | $1.75M | $1.87M | $1.70M | $1.54M | $1.15M | $0 | $0 |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $3.21M |
| Shareholder equity | $1.02B | $1.06B | $621.09M | $349.45M | $301.51M | $198.27M | $100.40M | -$48.95M | -$15.74M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.22B | $1.31B | $1.03B | $1.11B | $1.19B | $1.04B | $1.10B | $1.12B | $1.24B | $973.66M | $961.53M | $649.32M |
| Total liabilities | $123.96M | $110.79M | $93.08M | $86.39M | $93.10M | $81.62M | $76.51M | $64.94M | $59.45M | $42.01M | $26.22M | $28.23M |
| Cash and equivalents | $261.45M | $272.59M | $157.52M | $112.83M | $298.93M | $114.64M | $130.00M | $84.38M | $400.28M | $183.05M | $108.34M | $157.02M |
| Shareholder equity | $1.09B | $1.20B | $937.27M | $1.02B | $1.09B | $959.65M | $1.02B | $1.06B | $1.18B | $931.66M | $935.31M | $621.09M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$71.10M | -$247.58M | -$115.22M | -$87.17M | -$55.78M | $55.46M | -$39.31M | -$27.62M | -$12.22M |
| Capital expenditures | $2.37M | $3.86M | $2.37M | $3.44M | $2.64M | $493.00K | $1.35M | $1.71M | $1.76M |
| Free cash flow | -$73.47M | -$251.44M | -$117.59M | -$90.62M | -$58.42M | $54.97M | -$40.67M | -$29.33M | -$13.98M |
| Investing cash flow | $69.98M | -$502.56M | -$158.46M | -$33.40M | -$69.67M | -$146.24M | $2.27M | -$63.18M | -$8.93M |
| Financing cash flow | $29.78M | $677.55M | $362.72M | $97.17M | $145.45M | $128.75M | $50.61M | $105.38M | $17.49M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$93.48M | -$88.21M | -$75.17M | -$90.50M | $142.21M | -$62.47M | -$60.34M | -$121.66M | -$49.23M | -$32.88M | -$43.81M | -$23.75M |
| Capital expenditures | $273.00K | $866.00K | $967.00K | $333.00K | $42.00K | $663.00K | $1.33M | $1.10M | $457.00K | $973.00K | $1.32M | $838.00K |
| Free cash flow | -$93.75M | -$89.08M | -$76.14M | -$90.83M | $142.17M | -$63.14M | -$61.67M | -$122.76M | -$49.69M | -$33.85M | -$45.14M | -$24.59M |
Frequently Asked Questions About IDYA
What is Ideaya Biosciences' annual revenue?
Ideaya Biosciences reported revenue of $218.71M for the fiscal year ended Dec 31, 2025.
How fast is Ideaya Biosciences' revenue growing?
Revenue was up 3024.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 62.5%.
Is Ideaya Biosciences profitable?
No. Ideaya Biosciences reported net income of -$113.70M for the fiscal year ended Dec 31, 2025, with a net margin of -52.0%.
How much free cash flow does IDYA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$71.10M minus capital expenditures of $2.37M produced free cash flow of -$73.47M.
How much debt does Ideaya Biosciences have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $339.00K and cash and equivalents of $112.83M.
IDYA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors